Amsbio now offers a ready-to-use range of lentiviral particles designed to deliver target genes into virtually any mammalian cell type, both dividing and non-dividing, in vitro and in vivo. These ...

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...

UCLA researchers use lipid nanoparticles to insert full CFTR gene into airway cells, restoring function and opening new avenues for CF therapy.

Viral vectors introduce genes and gene editing sequences into cells, and are a popular platform for gene therapy due to their safety and efficacy features. Adeno-associated viral (AAV) vectors in ...

Developers of gene therapies to treat knee osteoarthritis are taking the familiar intra-articular route to deliver proteins and molecules directly to the site of the disease.

Allied Market Research published a report, titled, "Viral Vectors and Plasmid DNA Manufacturing Market by Product (Plasmid DNA, Viral ...

Duchenne muscular dystrophy is the most common early onset form of muscular dystrophy; many boys become wheelchair bound in their teens and die in their twenties. People with limb girdle muscular ...

Key market opportunities lie in AAV gene therapy advancements for hereditary retinal diseases. Future prospects include combination with CRISPR for precise genome editing, novel delivery platforms, ...